Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Ann Oncol
; 35(1): 107-117, 2024 Jan.
Article
in En
| MEDLINE
| ID: mdl-37871702
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazoles
/
Quinoxalines
/
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
Limits:
Humans
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article